• Home
  • Daewoong Pharmaceutical Co.,Ltd

Daewoong Pharmaceutical Co.,Ltd

About Daewoong Pharmaceutical Co.,Ltd

Since its establishment in 1945, Daewoong Pharmaceutical has grown to become one of the top 5 pharmaceutical companies in Korea. With its strong and competent in-house R&D and qualified manufacturing facilities (cGMP), Daewoong provides a total healthcare solution to patients across the globe. We manufacture various products (ETC&OTC) including Biologic, Chemical, Medical Device, etc. 

Products: Finished Dosage Formulations (Biologic & Chemical), APIs, Antibiotics, Enzymes
Interests: In-licencing, Out-licensing, CDMO, Co-Development, Open Collaboration
...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2015
    On CPHI since
  • 1000 - 4999
    Employees
Company types
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Barcelona 2023

Fira Barcelona Gran Via, Spain
24-26 October 2023
View Exhibitor Profile

Products from Daewoong Pharmaceutical Co.,Ltd (5)

  • NABOTA

    Product NABOTA

    Botulinum toxin type A

    Indication: Glabella Lines (Approved in KR, US, Canada, on-going registration in EU), 
    Post Stroke Upper Limb Spasticity (Approved in KR), 
    Crow's feet (Approved in KR), Blepharospasm (Approved in KR)

    - NabotaTM is the only 900kDa neurotoxi...
  • Crezet

    Product Crezet

    1) Indication :  Treatment of primary hypercholesterolemia or to decrease elevated fat level in blood (mixed hyperlipidemia) in adult patients 
    2) Composition : Ezetimibe, Rosuvastain calcium (strength: 10/20mg, 10/10mg,10/5mg)
    3) Dosage & Administration : Once a day with or without m...
  • Enavogliflozin (SGLT2i)

    Product Enavogliflozin (SGLT2i)

    Enavogliflozin is a best-in-class SGLT2 inhibitor for T2DM.


    Highlights of Enavogliflozin:
    * NDA filed, Accelerated Approval granted by MFDS, expected market approval within 2022 for T2DM
    * T2DM Phase III was completed in Korea as a stand-alone and as combinations with other anti...
  • Epodion

    Product Epodion

    2000, 3000, 4000, 10000IU / Pre-filled syringe Inj.

    Albumin-FREE
    rhEPO (recombinant human erythropoietin)

    Indication:
    Anemia in chronic renal failure

    - EpodionTM is PFS type of Erytrhopoietin - alpha (rhEPO) for improving the hemoglobin and hematocrit level ...
  • Eposis

    Product Eposis

    2000, 3000, 4000, 5000, 6000, 8000, 10000IU / Pre-filled syringe Inj.

    rhEPO (recombinant human erythropoietin)

    Indication:
    Anemia in chronic renal failure

    - EposisTM demonstrated significant improvement and safety for patients with anemia in Chronic Renal Failure (CRF).
    ...

Daewoong Pharmaceutical Co.,Ltd Resources (2)

  • News Daewoong Pharm’s COVID-19 cure enters Phase 2 trial in Mexico

    An investigator-initiated Phase 2 clinical trial of Daewoong Pharm’s COVID-19 drug candidate has been kicked off at several health centers in Mexico, including Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. The sponsor-investigator study will evaluate the efficacy and safety profile of Foistar Tab. (camostat mesylate) in 180 COVID-19 patients with mild to moderate ...
    22 Sep 2020
  • DAEWOONG PR VIDEO (EN)

    Video DAEWOONG PR VIDEO (EN)